株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

肺炎桿菌(肺炎クレブシエラ)感染症:パイプライン製品の分析

Klebsiella pneumoniae Infections - Pipeline Review, H1 2017

発行 Global Markets Direct 商品コード 251627
出版日 ページ情報 英文 82 Pages
即納可能
価格
本日の銀行送金レート: 1USD=110.47円で換算しております。
Back to Top
肺炎桿菌(肺炎クレブシエラ)感染症:パイプライン製品の分析 Klebsiella pneumoniae Infections - Pipeline Review, H1 2017
出版日: 2017年05月16日 ページ情報: 英文 82 Pages
概要

肺炎桿菌(肺炎クレブシエラ)とはグラム陰性菌であり、肺炎桿菌感染症はこの菌が肺に入ることによって引き起こされます。この感染症は、糖尿病や慢性肺疾患、慢性アルコール依存症などの基礎疾患を持つ患者の間でよく見られ、多くの場合、免疫系の弱った入院患者が院内感染によって発症します。壊死、炎症、出血、悪寒、高熱、頭痛、胸の痛みなどの症状があり、治療には、抗生剤の利用や衛生的な生活などがあります。

当レポートでは、世界における肺炎桿菌(肺炎クレブシエラ)感染症治療薬のパイプラインについて取り上げ、現在の開発パイプラインの状況や最新動向、薬剤プロファイル、主要企業および開発中の製品レビューなどをお届けいたします。

目次

イントロダクション

  • 分析範囲

肺炎桿菌(肺炎クレブシエラ)感染症の概要

治療薬の開発

  • 肺炎桿菌(肺炎クレブシエラ)感染症向けパイプライン製品:概要
  • 企業別のパイプライン製品
  • 大学/研究機関別のパイプライン製品
  • 企業で開発中の製品
  • 大学/研究機関で開発中の製品

治療薬の評価

  • 標的別
  • 作用機序別
  • 投与経路別
  • 分子タイプ別

肺炎桿菌(肺炎クレブシエラ)感染症:治療薬開発に従事している企業

  • Appili Therapeutics
  • Cellceutix Corp
  • Debiopharm International SA
  • Evaxion Biotech ApS
  • F. Hoffmann-La Roche Ltd
  • FOB Synthesis Inc
  • ImmunoClin Corp
  • 杏林製薬
  • Melinta Therapeutics Inc
  • Nosopharm SAS
  • Peptilogics Inc
  • Pfizer Inc
  • Phico Therapeutics Ltd
  • Sarepta Therapeutics Inc
  • 塩野義製薬
  • Soligenix Inc
  • Syntiron LLC
  • Tetraphase Pharmaceuticals Inc

薬剤プロファイル

休止中のプロジェクト

開発中止の製品

製品開発マイルストーン

  • 注目のニュース・プレスリリース

付録

図表

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC9249IDB

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Klebsiella pneumoniae Infections - Pipeline Review, H1 2017, provides an overview of the Klebsiella pneumoniae Infections (Infectious Disease) pipeline landscape.

Klebsiella pneumoniae is a Gram-negative bacteria. A Klebsiella pneumoniae infection is caused when the organism is able to enter the lungs. A Klebsiella pneumoniae infection is very common in patients with underlying diseases like diabetes, chronic lung diseases and chronic alcoholics. It is mostly a nosocomial infection that occurs in hospitalized patients with weakened immune system. Symptoms include necrosis, inflammation, hemorrhage, chills, dizziness, high fever, head ache and chest pain. Treatment includes antibiotics and hygiene lifestyle.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Klebsiella pneumoniae Infections - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Klebsiella pneumoniae Infections (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Klebsiella pneumoniae Infections (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Klebsiella pneumoniae Infections and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase I, Preclinical and Discovery stages are 1, 1, 19 and 8 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 2 and 3 molecules, respectively.

Klebsiella pneumoniae Infections (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Klebsiella pneumoniae Infections (Infectious Disease).
  • The pipeline guide reviews pipeline therapeutics for Klebsiella pneumoniae Infections (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Klebsiella pneumoniae Infections (Infectious Disease) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Klebsiella pneumoniae Infections (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Klebsiella pneumoniae Infections (Infectious Disease)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Klebsiella pneumoniae Infections (Infectious Disease).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Klebsiella pneumoniae Infections (Infectious Disease) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Klebsiella pneumoniae Infections - Overview
    • Klebsiella pneumoniae Infections - Therapeutics Development
    • Pipeline Overview
    • Pipeline by Companies
    • Pipeline by Universities/Institutes
    • Products under Development by Companies
    • Products under Development by Universities/Institutes
  • Klebsiella pneumoniae Infections - Therapeutics Assessment
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Klebsiella pneumoniae Infections - Companies Involved in Therapeutics Development
    • Appili Therapeutics
    • Cellceutix Corp
    • Debiopharm International SA
    • Evaxion Biotech ApS
    • F. Hoffmann-La Roche Ltd
    • FOB Synthesis Inc
    • ImmunoClin Corp
    • Kyorin Pharmaceutical Co Ltd
    • Melinta Therapeutics Inc
    • Nosopharm SAS
    • Peptilogics Inc
    • Pfizer Inc
    • Phico Therapeutics Ltd
    • Sarepta Therapeutics Inc
    • Shionogi & Co Ltd
    • Soligenix Inc
    • Syntiron LLC
    • Tetraphase Pharmaceuticals Inc
  • Klebsiella pneumoniae Infections - Drug Profiles
    • Antisense Oligonucleotide to Inhibit NDM-1 for Klebsiella Pneumoniae Infections - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ASN-300 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ATI-1503 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CA-824 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CC-1807 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • cefiderocol - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Debio-1454 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • dusquetide - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • EBX-004 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • FSI-1671 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • FSI-1686 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • GNeg Snare - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • IBN-1 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • interleukin-22 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Klebsiella pneumoniae vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Klebsiella pneumoniae vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Klebsiella pneumoniae vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • mirandamycin - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • NOSO-95179 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Onc-72 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • OTP-602 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Peptides for Infectious Diseases - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • PT-4 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • RX-05 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • RXP-873 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule to Inhibit Lipopolysaccharide for Nosocomial Infections - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule to Inhibit LpxC for Gram-Negative Bacterial Infections - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules for Bacterial and Fungal Infections - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules for Bacterial Infections - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules for Bacterial Infections - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules for Klebsiella pneumoniae Infections - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules for Multi-Drug Resistant Gram-Positive and Gram-Negative Bacterial Infections - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • TP-6076 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • WLBU-2 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Klebsiella pneumoniae Infections - Dormant Projects
  • Klebsiella pneumoniae Infections - Discontinued Products
  • Klebsiella pneumoniae Infections - Product Development Milestones
    • Featured News & Press Releases
      • Apr 20, 2017: Arsanis Presents Data on ASN-300 at the 27th European Congress of Clinical Microbiology and Infectious Diseases
      • Apr 11, 2017: Appili Therapeutics Receives Funding from the Government of Canada to Support Development of New Antibiotic To Treat Gram-Negative Infections
      • Jun 17, 2016: Arsanis Presents Data at ASM Microbe 2016 Demonstrating Protection Against Klebsiella pneumoniae using Monoclonal Antibody Technology
      • Mar 09, 2015: Phico Therapeutics Receives Translation Award to Advance its SASPject PT4 Aimed at Escherichia coli and Klebsiella pneumoniae Towards Clinical Trials
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development for Klebsiella pneumoniae Infections, H1 2017
  • Number of Products under Development by Companies, H1 2017
  • Number of Products under Development by Companies, H1 2017 (Contd..1), H1 2017
  • Number of Products under Development by Universities/Institutes, H1 2017
  • Products under Development by Companies, H1 2017
  • Products under Development by Companies, H1 2017 (Contd..1), H1 2017
  • Products under Development by Universities/Institutes, H1 2017
  • Number of Products by Stage and Target, H1 2017
  • Number of Products by Stage and Mechanism of Action, H1 2017
  • Number of Products by Stage and Route of Administration, H1 2017
  • Number of Products by Stage and Molecule Type, H1 2017
  • Klebsiella pneumoniae Infections - Pipeline by Appili Therapeutics, H1 2017
  • Klebsiella pneumoniae Infections - Pipeline by Cellceutix Corp, H1 2017
  • Klebsiella pneumoniae Infections - Pipeline by Debiopharm International SA, H1 2017
  • Klebsiella pneumoniae Infections - Pipeline by Evaxion Biotech ApS, H1 2017
  • Klebsiella pneumoniae Infections - Pipeline by F. Hoffmann-La Roche Ltd, H1 2017
  • Klebsiella pneumoniae Infections - Pipeline by FOB Synthesis Inc, H1 2017
  • Klebsiella pneumoniae Infections - Pipeline by ImmunoClin Corp, H1 2017
  • Klebsiella pneumoniae Infections - Pipeline by Kyorin Pharmaceutical Co Ltd, H1 2017
  • Klebsiella pneumoniae Infections - Pipeline by Melinta Therapeutics Inc, H1 2017
  • Klebsiella pneumoniae Infections - Pipeline by Nosopharm SAS, H1 2017
  • Klebsiella pneumoniae Infections - Pipeline by Peptilogics Inc, H1 2017
  • Klebsiella pneumoniae Infections - Pipeline by Pfizer Inc, H1 2017
  • Klebsiella pneumoniae Infections - Pipeline by Phico Therapeutics Ltd, H1 2017
  • Klebsiella pneumoniae Infections - Pipeline by Sarepta Therapeutics Inc, H1 2017
  • Klebsiella pneumoniae Infections - Pipeline by Shionogi & Co Ltd, H1 2017
  • Klebsiella pneumoniae Infections - Pipeline by Soligenix Inc, H1 2017
  • Klebsiella pneumoniae Infections - Pipeline by Syntiron LLC, H1 2017
  • Klebsiella pneumoniae Infections - Pipeline by Tetraphase Pharmaceuticals Inc, H1 2017
  • Klebsiella pneumoniae Infections - Dormant Projects, H1 2017
  • Klebsiella pneumoniae Infections - Dormant Projects, H1 2017 (Contd..1), H1 2017
  • Klebsiella pneumoniae Infections - Discontinued Products, H1 2017

List of Figures

  • Number of Products under Development for Klebsiella pneumoniae Infections, H1 2017
  • Number of Products under Development by Companies, H1 2017
  • Number of Products under Development by Universities/Institutes, H1 2017
  • Number of Products by Top 10 Targets, H1 2017
  • Number of Products by Stage and Top 10 Targets, H1 2017
  • Number of Products by Top 10 Mechanism of Actions, H1 2017
  • Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017
  • Number of Products by Routes of Administration, H1 2017
  • Number of Products by Stage and Routes of Administration, H1 2017
  • Number of Products by Top 10 Molecule Types, H1 2017
  • Number of Products by Stage and Top 10 Molecule Types, H1 2017
Back to Top